[Topical therapy with placental polydeoxyribonucleotide in cervical ectopy and ectropion].
Twenty outpatients, aged 18-45 yrs, with cervical ectropion have been treated with vaginal suppositories of PDRN (a placental derivate). The drug has been given randomly in two preparations of 5 g and 10 g, however both containing the same amount of the active component (5 mg). The results show the effectiveness of the eutrophic and antiphlogistic action of both preparations, with a remarkable reduction of the leukorrhea. The patients preferred the vaginal suppositories of 5g both for the greater maniability and for the smaller vaginal discharge after the administration. The reduction of the excipients in the new vaginal tablets, besides improving the compliance of patients, brings about a longer contact of the drug with the vaginal walls, hence a better bioavailability of the active principle.
de Luca Brunori
I
I
Battini
L
L
Filippeschi
M
M
Romani
L
L
Tarani
A
A
Urbano
M
M
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007973:Leukorrhea / Q000209:etiology; D008875:Middle Aged; D010349:Patient Compliance; D010570:Pessaries; D010920:Placenta; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D002577:Uterine Cervical Diseases / Q000188:drug therapy*
D011089:Polydeoxyribonucleotides
Terapia topica con polidesossiribonucleotide placentare nella ectopia e nell'ectropion cervicali.